Report
EUR 13.42 For Business Accounts Only

Increased risk weighs on ACCURAY, penalising its rating down to Slightly Negative

The independent financial analyst theScreener just lowered the general evaluation of ACCURAY (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title still shows 1 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date September 10, 2021, the closing price was USD 3.66 and its target price was estimated at USD 2.79.
Underlying
Accuray

Accuray is a radiation oncology company that develops, manufactures, sells and supports treatment solutions for radiation therapy care. The company's technologies are: CyberKnife Systems, which automatically track, detect and correct for tumor and patient movement in real-time during the procedure, enabling delivery of high dose radiation with sub-millimeter accuracy while patients breathe normally, without manual user intervention; and TomoTherapy Systems, including the Radixact System, which represents a radiation therapy platform specifically designed for image-guided intensity-modulated radiation therapy. The company also provides its Onrad Treatment Delivery System in China.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch